Expert Directory

Showing results 1 – 5 of 5

Liver Cancer, Pancreatic, Cancer, Pancreatic Cancer, abdominal cancer , Gastrointestinal Cancer, Stomach Cancer, Gallbladder Cancer

Chief Medical Officer, Roswell Park Cancer Institute
Areas of expertise: Liver cancer, pancreatic cancer, abdominal tumors, stomach cancer, gallbladder cancer, gastrointestinal cancer

Angela Alistar MD, MD

Medical Director, GI Medical Oncology, Morristown Medical Center

Atlantic Health System

Gastrointestinal Cancer, Pancreatic Cancer, Clinical Trials, gi medical oncology researcher, Precision Oncology, Immunotherapy, inmmuno-oncology, cancer metabolism

Dr. Angela Alistar is a board-certified medical oncologist with Atlantic Hematology Oncology, Atlantic Medical Group.  Dr. Alistar is Medical Director of GI Medical Oncology at Morristown Medical Center where she is also Medical Director of the Phase 1 Breakthrough Treatment Center.  Her research focus is related to immuno-oncology and cancer metabolism in gastrointestinal cancer such as: pancreatic tumors, cholangiocarcinoma, colorectal, esophageal, gastric cancer and hepatocellular carcinoma. Her clinical research projects involved active collaborative efforts with other medical departments, such as radiation oncology and surgical oncology, as well as genomics and cancer biology.

Recently, she has published in Lancet Oncology the results of a Phase 1 clinical study in pancreatic cancer that are very promising for advancing the field for this disease. This study has shown impressive synergy of a novel agent, CPI -613 in combination with chemotherapy. She is co-leading the national multi-site, randomized study of this promising combination, as well as many other phase 1-3 clinical trials.

Dr. Alistar comes to Atlantic Health System from Wake Forest School of Medicine where she had a heavy emphasis on clinical trials and clinical research. At Wake Forest, she led the GI oncology disease oriented team as a gastrointestinal medical oncology physician and researcher, bringing cutting-edge treatments to patients. She designed, secured funding for and conducted five investigator-initiated therapeutic clinical trials, with four of them being phase one. Her work involved maintenance of a sponsor-investigator investigational new drug. She is passionate about Precision Oncology and Immunotherapies and seeks to identify novel treatment strategies for her patients.

Past positions at Wake Forest include being a member of the Translational Cancer Genomics Committee, the GI Tumor Board, Internal Medicine Grand Rounds, and the Hepatobiliary Oncology Committee. She is a member of several health care organizations, such as the American Society of Clinical Oncology, the American Society of Hospice and Palliative Care Medicine, and the American Society of Hematology, among many others. As well, she is a member and advisor for several other health care institutions. She was recently awarded the "Danny Danielson Translational Innovation Award" by Hoosier Cancer Research Network for her commitment to clinical research. 

She received her medical degree from University of Medicine and Pharmacy, Cluj Napoca, Romania and her residency at Englewood Hospital and Medical Center, NJ, where she was chief resident. After her residency, she completed a hematology oncology fellowship at Mount Sinai School of Medicine, Tisch Cancer Institute. She is affiliated with Atlantic Medical Group, and is a participating provider of Atlantic Accountable Care Organization, and sees patients at Morristown Medical Center.

Gastrointestinal Cancer, Pancreatic Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer

Weijing Sun, MD, FACP, is a Director of Division of Medical Oncology in University of Kansas School of Medicine, and an Associate Director of University of Kansas Cancer Center. He specializes in the treatment of colorectal cancer.

Dr. Sun is board-certified in internal medicine and medical oncology. He received his medical degree from Shanghai Medical College, Fudan University, in Shanghai. He completed his residency in internal medicine at Loyola University Medical Center in Maywood, Ill., and his hematology-oncology fellowship at the University of Pennsylvania in Philadelphia.

Dr. Sun is a member of the American Medical Association, the American Society of Clinical Oncology, the American Association of Cancer Research, the Eastern Cooperative Group of Oncology Gastrointestinal Cancer Core Committee, the American College of Physicians – Internal Medicine, the NCI Gastrointestinal Cancer Steering Committee Hepatobiliary Task Force, and serves on the American Society of Clinical Oncology Scientific Program and Membership Committee. In addition, Dr. Sun has been recognized on U.S. News & World Report’s American Top Doctors list.

Neuroendocrine Tumors, Thyroid Cancer, parathyroid tumors, Pancreatic Cancer, Liver Cancer, Minimally Invasive Surgery

Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university’s partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at the Rutgers School of Arts and Sciences Department of Genetics.

Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.

The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.

After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch.  He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents. 

Clinical Expertise:
Neuroendocrine tumors, thyroid cancer, parathyroid tumors, pancreatic cancer, liver cancer, gastrointestinal (GI) cancers, minimally invasive surgery, and clinical trials.
Cosimo Commisso, Ph.D., studies pancreatic cancer, one of the deadliest cancers. He is particularly interested in how the tumor gets nutrients from its environment, as cutting this fuel supply could stop the cancer’s growth.

Showing results 1 – 5 of 5

close
1.30488